conclusion of the procedure. At the time of drug administration, surgeons became unblinded, but did not collect outcome data. Participants remained blinded to treatment. Surgical procedures and perioperative care were standardized. The primary outcome was Visual Analog Scale (VAS) pain score 4 hours after discharge home. Secondary outcomes included narcotic consumption, time to first bowel movement, and VAS pain scores collected in the mornings and evenings until postoperative day (POD) 6. The morning VAS item assessed "current level of pain," and evening items queried "current level of pain," "most intense pain today," "average pain today with activity," and "average pain today with rest." Likert scales were used to measure satisfaction with pain control at 1 and 2 week postoperative intervals. Sample size calculation deemed 52 subjects per arm necessary to detect a mean difference of 10 mm on 100 mm VAS. To account for 10% drop out, 114 participants were needed. RESULTS: One hundred fourteen women were enrolled. After 5 exclusions, 109 were analyzed: 54 received LB, and 55 received P. Mean participant age was 52 years, and mean BMI was 30.4. Surgical and demographic characteristics were similar except a slightly higher BMI in the P arm (31.6 vs 29.2, p ¼ 0.050), and more subjects received midazolam during anesthesia induction in the LB arm (52 vs 44, p ¼ 0.015). For the primary outcome, the VAS pain score (mm) was lower in the LB group 4 hours after discharge home (3.5 vs 13, p ¼ 0.014). VAS scores were also lower for LB subjects at the following collected time points: POD 1 morning "current level of pain" (9.5 vs 27, p ¼ 0.014), POD 2 "average pain with rest" (5.5 vs 10, p ¼ 0.027), POD 3 morning "current level of pain" (6 vs 10, p ¼ 0.011), and POD 3 "average pain with rest" (4 vs 7, p ¼ 0.043). Furthermore, fewer LB participants consumed narcotic medication on POD 2 (12 vs 27, p ¼ 0.006). There was no difference in satisfaction with pain control between groups. Side effects experienced, rate of postoperative urinary retention, and time to first bowel movement were also similar between arms. Finally, no serious adverse events were noted. CONCLUSION: Liposomal bupivacaine decreased postoperative pain scores following retropubic midurethral sling placement. Participants who received liposomal bupivacaine were also less likely to use narcotics on POD 2. No differences in side effects or adverse events were observed between groups. For this common outpatient surgery, liposomal bupivacaine may be a beneficial addition for pain control.
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MATERIALS AND METHODS:
This was a prospective, randomized, patient-blinded, placebo-controlled trial of patients undergoing robotic-assisted sacrocolpopexy with rectocele repair. Either liposomal bupivacaine or normal saline was injected subcutaneously into laparoscopic port sites and posterior repair incision at the completion of surgery. Perioperative care was standardized for both groups. Visual analog scales (VAS) were collected in the hospital at 4, 18, and 24 hours following surgery. Upon discharge, participants were asked to complete twice daily VAS questionnaires and a pain medication diary until postoperative day 3. The primary outcome was VAS for pain 18 hours after surgery. Secondary measures included nursing administered verbal pain scores, satisfaction with pain control, narcotic use (morphine equivalents), location of "the most painful" site, voiding trial results, and time to first bowel movement. Our sample size calculation revealed 32 subjects per arm were required to detect a mean difference of 20 mm on the Visual Analog Scale (VAS). To allocate for dropout, a goal of 70 was set. RESULTS: Seventy patients were enrolled; 6 were excluded: 2 converted to vaginal repairs, 2 withdrew after randomization, 1 patient had an elevated creatinine, and 1 reported a history of cocaine abuse. Sixty-four subjects were analyzed: 33 received liposomal bupivacaine (LB) and 31 received normal saline (NS). The mean age was 62 (SD 13), and mean body mass index was 27.3 (SD 6.9). There was no difference in demographics, surgical data, voiding trial results, time to first bowel movement, or satisfaction scores between the cohorts. While the median VAS score at 18 hours after surgery was lower for those who received liposomal bupivacaine ( When comparing all abdominal incisions, participants noted the umbilical site to be the most painful. However, there was no significant difference between overall abdominal incision pain and vaginal incision pain among or between groups. Most common reported side effects included nausea, itching, insomnia, and irritation at the injection sites, with no differences based on treatment allocation. CONCLUSION: In this study of robotic assisted sacrocolpopexy with rectocele repair, there was no significant difference in VAS scores or narcotic use between liposomal bupivacaine and normal saline for local analgesia. A modest benefit was noted only in nursing administered pain scores. Given potential increased expense and risk of adverse events with liposomal bupivacaine, we do not support its routine use for this surgical intervention.
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